91 percent response rate for venetoclax against newly diagnosed AML in older adults
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients ...
Nov 28, 2018
0
72